GENERAL THORACIC SURGERY LONG-TERM RESULTS OF LUNG METASTASECTOMY : PROGNOSTIC ANALYSES BASED ON 5206 CASES The International Registry of Lung Metastases
GENERAL THORACIC SURGERY LONG-TERM RESULTS OF LUNG METASTASECTOMY : PROGNOSTIC ANALYSES BASED ON 5206 CASES The International Registry of Lung Metastases
复制标题
普通胸外科肺转移切除术的长期结果：基于 5206 例病例的预后分析 国际肺转移登记处
DOI：
--
复制
发表时间：
2004
期刊：
影响因子：
--
通讯作者：
Joe B. Putnam
中科院分区：
文献类型：
--
作者：
Ugo Pastorino;Marc Buyse;Godehard Friedel;R. Ginsberg;Philippe Girard;Peter Goldstraw;Michael Johnston;Patricia M. McCormack;Harvey I. Pass;Joe B. Putnam
国际肺转移登记*撰写委员会：Ugo Pastorino，MD Marc Buyse，ScD Godehard Friedel，MD Robert J.Ginsberg，MD Philippe Girard，MD Peter Goldstraw，MD Michael Johnston，MD Patricia McCormack，MD Harvey Pass，MD Joe B.Putnam，Jr.目的：国际肺转移登记成立于1991年，目的是评估肺转移切除的长期结果。方法：从欧洲(n=13)、美国(n=4)和加拿大(n=1)的18个开胸外科收集了5206例肺转移瘤切除病例。在这些患者中，4572例(88%)接受了完全手术切除。原发肿瘤为上皮性肿瘤2260例，肉瘤2173例，生殖细胞瘤363例，黑色素瘤328例。无病间隔时间为0~11个月者2199例，12~35个月者1857例，36个月以上者1620例。单发转移2383例，多发2726例。平均随访时间为46个月。采用Kaplan Meier生存估计值、相对死亡风险和多变量Cox模型进行分析。结果：5年、10年和15年(中位35个月)转移瘤完全切除后的精算生存率分别为36%、26%和22%，不完全切除的5年和10年(中位15个月)的生存率分别为113%和7%。在完全切除中，无病间隔0~11个月的患者的5年生存率为33%，无病间隔超过36个月的患者的5年生存率为45%，单个病变的5年生存率为43%，4个或更多病变的5年生存率为27%。多因素分析显示，生殖细胞肿瘤、无病间隔36个月或更长时间和单发转移的患者预后较好。结论：这些结果证实肺转移瘤切除术是一种安全且有潜在疗效的手术。可切除性、无瘤间隔和转移数量使我们能够设计一种简单的分类系统，对不同的肿瘤类型有效。(胸心外科杂志1997；113：37-49)
The International Registry of Lung Metastases* Writing Committee: Ugo Pastorino, MD Marc Buyse, ScD Godehard Friedel, MD Robert J. Ginsberg, MD Philippe Girard, MD Peter Goldstraw, MD Michael Johnston, MD Patricia McCormack, MD Harvey Pass, MD Joe B. Putnam, Jr., MD Objectives: The International Registry of Lung Metastases was established in 1991 to assess the long-term results of pulmonary lnetastasectomy. Methods: The Registry has accrued 5206 cases of lung metastasectomy, from 18 departments of thoracic surgery in Europe (n = 13), the United States (n = 4) and Canada (n = 1). Of these patients, 4572 (88%) underwent complete surgical resection. The primary tumor was epithelial in 2260 cases, sarcoma in 2173, germ cell in 363, and melanoma in 328. The disease-free interval was 0 to 11 months in 2199 cases, 12 to 35 months in 1857, and more than 36 months in 1620. Single metastases accounted for 2383 cases and multiple lesions for 2726. Mean follow-up was 46 months. Analysis was performed by KaplanMeier estimates of survival, relative risks of death, and multivariate Cox model. Results: The actuarial survival after complete metastasectomy was 36% at 5 years, 26% at 10 years, and 22% at 15 years (median 35 months); the corresponding values for incomplete resection were 113% at 5 years and 7% at 10 years (median 15 months). Among complete resections, the 5-year survival was 33% for patients with a disease-free interval of 0 to 11 months and 45% for those with a disease-free interval of more than 36 months; 43% for single lesions and 27% for four or more lesions. Multivariate analysis showed a better prognosis for patients with germ cell tumors, disease-free intervals of 36 months or more, and single metastases. Conclusions: These results confirm that lung metastasectomy is a safe and potentially curative procedure. Resectability, disease-free interval, and number of metastases enabled us to design a simple system of classification valid for different tumor types. (J Thorac Cardiovasc Surg 1997;113:37-49)
成骨肉瘤：辅助化疗肺转移模式的改变。
DOI：
10.1200/jco.1983.1.4.251
发表时间：
1983
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Jaffe,N;Smith,E;Abelson,HT;Frei3rd,E
通讯作者：
Frei3rd,E
影响因子：
45.3
作者：
EILBER, F;GIULIANO, A;GOODNIGHT, J
通讯作者：
GOODNIGHT, J